Treat Pain at the Source with Efficacy that Lasts for up to 72 Hours
EXPAREL is the only single-dose local analgesic that provides
- Up to 72 hours of non-opioid analgesia with
- Reduced or eliminated opioid requirements
- Without the need for catheters and pumps
Pivotal studies have demonstrated the safety and efficacy of EXPAREL in patients undergoing bunionectomy and hemorrhoidectomy procedures.
Through 72 hours, EXPAREL demonstrated a significant reduction in pain and opioid use in a pivotal soft tissue trial.
click charts to enlarge
In the same study, EXPAREL significantly delayed opioid use and eliminated opioid requirements altogether for 28% of EXPAREL patients compared to 10% of placebo patients.
The clinical benefit of the attendant decrease in opioid consumption was not determined.
click charts to enlarge
EXPAREL is contraindicated in obstetrical paracervical block anesthesia. EXPAREL has not been studied for use in patients younger than 18 years of age.
Learn About EXPAREL
View the infiltration technique for EXPAREL. > More
Is EXPAREL Right for My Patients?
Find out if EXPAREL could meet a need in your practice. > More
EXPAREL Monograph
Get an overview of postsurgical pain management and EXPAREL treatment options. > More
These are not all of the potential important safety considerations for EXPAREL, please see the full Prescribing Information.
To report an adverse event, e-mail drugsafety@pacira.com or dial 1-855-RX-EXPAREL (1-855-793-9727).
For medical inquiries related to EXPAREL, contact Medical Information at medinfo@pacira.com or 1-855-RX-EXPAREL (1-855-793-9727).
Reference:
- Gorfine SR, Onel E, et al. Bupivacaine extended-release liposome injection for prolonged postsurgical analgesia in patients undergoing hemorrhoidectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Diseases of the Colon & Rectum. 2011;54(12):1552-1559.
Important Safety Information
EXPAREL is contraindicated in obstetrical paracervical block anesthesia. EXPAREL has not been studied for use in patients younger than 18 years of age.
Non-bupivacaine-based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from EXPAREL if administered together locally. The administration of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Other formulations of bupivacaine should not be administered within 96 hours following administration of EXPAREL.
Monitoring of cardiovascular and neurological status, as well as vital signs should be performed during and after injection of EXPAREL as with other local anesthetic products. Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations.
In clinical trials, the most common adverse reactions (incidence ≥10%) following EXPAREL administration were nausea, constipation, and vomiting. Please see the full Prescribing Information for EXPAREL.
